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Abstract  
Objectives The objective of this study was to evaluate the outcome of cats with intracranial tumors 
presenting with neurological signs treated with radiation therapy. 
Methods Retrospective multicenter case series. Medical records of a total of 22 cats with 
intracranial space-occupying lesions, presenting with neurologic signs and/or epileptic seizures, and 
treated with external beam radiation therapy, were reviewed. In the treated cats we investigated patient-, 
tumor- and treatment-related variables, including age, sex, tumor location, tumor volume, total radiation 
dose, EQD2, corticosteroid dose, overall treatment time and institution for influence on local tumor control 
and survival.  
Results  Based on advanced imaging characteristics, the 22 treated cats presented with 
meningioma (n=11), pituitary tumor (n=8), choroid plexus tumor (n=2), or glioma (n=1). Allocated to the 
neuraxis, 11 lesions were extra-axial, 3 intra-axial and 8 were located in the pituitary region. At diagnosis, 
21 cats exhibited altered neurological status. One cat presented with epileptic seizures and another cat had 
both seizures and altered neurological status. The mean total physical dose of radiation was 41.63 Gy (± 
4.33), range 24-45 Gy. In all but one cat (95.5%), neurological signs improved after radiation therapy. The 
median progression free survival (PFS) was 510 days (95%CI: 51;969). The proportion free of progression 
at 1 year was 55.7% (95%CI: 33;78). Fourteen cats died (only in 5 cases death was related to the 
intracranial tumor) and 8 cats were still alive or lost to follow up. The median overall survival time (OS) 
was 515 days (95%CI: 66;964). None of the tested variables influenced outcome. 
Conclusion and relevance Radiation therapy seems to represent a viable treatment option in cats with 
intracranial tumors, relieving neurological signs and improving local tumor control. Radiation therapy 
may be considered for cats with tumors in complicated/inoperable localizations or for cases with a high 
peri- and postoperative risk. 
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Introduction  
Neurological signs in cats with primary intracranial tumor are common and include altered consciousness 
(36.8%), circling (31.6%), and epileptic seizures (31.6%).1 Symptomatic therapy such as corticosteroids 
and/or antiepileptic medications provides only short-term relief. Prognosis in these conservatively 
managed patients is poor, with reported survival of 18 days.1-3 Complete or partial eradication of the tumor 
with surgery is desired in the management of intracranial disease and often results in improvement or 
resolution of neurologic signs.  
The most frequently occurring brain tumor in cats is meningioma.1, 4 Feline meningioma is often 
non-invasive (WHO grade 1) and located peripherally in the calvarium1, 4, which often makes surgery the 
treatment of choice. Surgical excision results in favorable long-term outcomes with a median survival of 
22.8-37 months.1, 2, 5 However, invasive tumors or tumors located at non-peripheral locations within the 
calvarium may be difficult to remove or may not be amenable to surgery.3 Treatment options for cats with 
inoperable intracranial tumors are not well described. In dogs with primary intracranial neoplasia of any 
type presenting with neurologic signs, radiation therapy is considered one of the treatments of choice. 
After radiation therapy, an improvement within 6 months or resolution of neurological signs associated 
with a long-term survival in the range of 2 years is observed in dogs with brain tumors.6-9 In cats, response 
to ionizing radiation and subsequent tumor control are not known. The few studies that describe response 
to radiation therapy in cats presented with neurological signs caused by an intracranial tumor are limited 
to pituitary tumors but indicate that neurologic amelioration can occur.10-13  
In this retrospective multicenter cases series, we describe the progression free – and overall 
survival in cats with intracranial tumors presented with neurological signs after treatment with 
radiotherapy (RT). We investigated the influence of patient-, tumor- and treatment-related variables on 
local control and survival.  
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Materials and Methods  
Patients 
The databases of the Division of Radiation Oncology of the Vetsuisse Faculty, University of Zurich 
(Switzerland), the Centro Oncologico Veterinario (Italy), the Royal (Dick) School of Veterinary Studies, 
Radiation Oncology Department, University of Edinburgh (UK) and the University of Wisconsin-Madison 
Veterinary Medical Teaching Hospital (USA) were searched for cats with primary, non-lymphoid 
intracranial space-occupying lesions with imaging diagnosis of a tumor, presented with neurologic signs 
that had been treated with radiation therapy alone between January 2002 and June 2017. Cats that had 
undergone surgery (complete excision or debulking) or received any type of systemic anticancer treatment 
such as chemotherapy were excluded from the study. Contributing veterinary radiation oncologists were 
asked to collect information from the medical record of each case including signalment, neurologic signs, 
diagnostic tests, tumor localization, and imaging-based diagnosis, medical management (i.e. 
corticosteroids), radiation therapy protocol and survival time. The space-occupying lesions in the brain 
were diagnosed from board certified radiologist either by contrast-enhanced computed tomography (CT) 
or magnetic resonance imaging (MRI). Due to the lack of histological diagnosis, the lesions were allocated 
to one of three groups according to their imaging characteristics: A) extra-axial tumors (consistent with 
meningioma, schwannoma, and choroid plexus tumor), B) intra-axial tumors (consistent with glioma), and 
C) pituitary tumors (consistent with adenoma and adenocarcinoma of the pituitary gland).7, 14 A second 
grouping was made according to the location of the tumor relative to calvarial anatomy: 1) rostral cranial 
fossa (rostral to the optic chiasm), 2) middle cranial fossa (between the optic chiasm and the dorsum sellae 
and petrosal crests: pituitary/temporal region), and 3) caudal cranial fossa (between the dorsum sellae and 
petrosal crests and the foramen magnum: including brain stem and cerebellum).15 Lesions suspicious for 
lymphoma (based on diagnostic imaging criteria) were excluded.14 The patients neurologic signs at the 
time of diagnosis were grouped into 3 categories: A) patients with altered neurologic status (changes in 
mentation and behavior, gait and postural abnormalities, deficits of cranial nerves including central 
blindness and head tilt), B) patients with epileptic seizures only, C) patients with epileptic seizures and 
altered neurologic status. Other information recorded included medical treatment at the time of diagnosis, 
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findings regarding tumor staging and if available, cerebrospinal fluid analysis. 
 
Treatment  
All cats were treated with external beam megavoltage radiation therapy. Radiation was delivered with 6 
MV linear acceleratorsa. Treatment planning was performed by a board-certified veterinary radiation 
oncologist in all cases, on the basis of 3D-CT datasets and using computerized radiation treatment 
planning systemsb.  Treatment planning CT scans were performed with each patient in treatment position 
using a customized immobilization device according to each institution’s standard practice.16 The gross 
tumor volume (GTV) was defined as the abnormal contrast-enhancing tissue on CT or MRI images. The 
clinical tumor volume (CTV) was added at the radiation oncologist’s discretion and a planning target 
volume (PTV) was added to include a safety margin accounting for systematic and random uncertainties. 
Organs at risk (normal brain tissue and eyes) were contoured in all cats. Radiation treatment was planned 
isocentrically using photons and 3-dimensional conformal radiation therapy. Beam shaping devices such 
as lead blocks, multi-leaf collimators and wedges were used to improve homogeneity and to minimize 
dose to organs at risk. In general, the dose was prescribed according to the International Commission on 
Radiation Units and Measurements.17, 18 Irradiation was delivered in various fractionated regimes. 
Follow-Up  
Contributing veterinary radiation oncologists gathered the post-radiotherapy follow-up information from 
the patients’ records. If a follow-up diagnostic imaging study was available, tumor response was 
quantified according to the RECIST guidelines for dogs.19 The sum of diameters of all target lesions was 
calculated and reported as the baseline sum diameter. Complete remission (CR) was defined as the 
disappearance of all target lesions. Partial response (PR) was defined as a reduction of at least 30% in the 
sum of diameters of target lesions from baseline. Progressive disease (PD) was defined as an increase in 
the sum of diameters of target lesions by at least 20% over baseline, or the appearance of new lesions. 
Tumors that neither showed sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD 
were considered to be of stable disease (SD). For cats that were not re-evaluated at one of the participating 
centers, the referring veterinarians and owners were queried by telephone regarding performance status, 
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neurologic signs compared to those at the time of diagnosis, disease progression and date of death by one 
of the authors (MKO, MPA or SCA).  
Statistical Analysis  
Statistical evaluation was performed under the supervision of a biostatistician (MR) and computed with a 
commercial statistical software package (IBM® SPSS® Statistics, Version 24). Data was used as submitted 
in a excel table by the contributing veterinary radiation oncologists. Description of quantitative data 
characteristics, other than progression-free survival (PFS) and overall survival (OS), is given by mean (± 
SD), unless otherwise specified. Description of qualitative characteristics is provided in absolute and 
relative frequencies. PFS was defined as the interval between the first day of radiation therapy to 
measurable progression of disease, worsening of neurologic signs compared to the neurologic status 
before RT or death. OS was defined as the interval between the first fraction of radiation therapy and 
death. Cats that were free of progression of measurable tumor and of progression of neurologic signs and 
that were alive at the time of data collection were censored for PFS analysis. For OS, all deaths were 
considered events and cats that were still alive at the time of data collection or lost to follow-up were 
censored at the last date of contact. Kaplan-Meier survival analysis was used and followed by Logrank 
test. The univariate Cox-regression analysis was used to determine whether the following factors were 
associated with PFS or OS: age, sex, meningioma/ non-meningioma, meningioma/ pituitary tumor, tumor 
volume (GTV, GTV/brain ratio), treatment volume (PTV, PTV/brain ratio), tumor location, treatment 
institution, dose of radiation (total dose, EQD2), dose of corticosteroids at first RT fraction, overall 
treatment time (counted from the first to the last fraction of RT). The equivalent dose in 2 Gy fractions 
(EQD2) was used to compare the different radiation protocols. Survival estimates at a certain time point 
are presented as percentage with the corresponding 95% confidence intervals (95%CI). Median survival 
time estimates are complemented with 95%CI. The paired Wilcoxon test evaluated the change in 
corticosteroid dose from the first to the last RT fraction. Results of statistical analyses with p-value <0.05 
were interpreted as statistically significant.  
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Results 
Patient and tumor characteristics 
Twenty-two cats met the inclusion criteria for this study. Nine of the cats were female (9 spayed) and 13 
were male (12 neutered). The presented breeds included domestic short-hair (n=18), Persian (n=3) and 
Selkirk Rex (n=1). The mean age was 12.0 years (± 2.3) and ranged from 6.5 - 16.4 years. The mean body 
weight was 4.5 kg (± 1.4) and ranged from 2.3 - 8.3 kg. Fifteen animals were treated at the Division of 
Radiation Oncology of the Vetsuisse Faculty, University of Zurich, Switzerland, 6 animals at the Centro 
Oncologico Veterinario, Sasso Marconi, Bologna, Italy, and 1 animal was treated at the Royal (Dick) 
School of Veterinary Studies at the Radiation Oncology of the University of Edinburgh, United Kingdom. 
There were no cats that met the inclusion criteria from the University of Wisconsin-Madison Veterinary 
Medical Teaching Hospital, USA. 
Based on imaging characteristics, tumors were diagnosed as meningioma (n=11), pituitary tumor 
(n=8), choroid plexus tumor (n=2), or glioma (n=1). Eleven tumors were considered extra-axial, 3 intra- 
axial and 8 were located in the pituitary region. Tumors were distributed in the cranial fossa (n=9), middle 
fossa (n=8) or caudal fossa (n=5). The pretreatment tumor volumes (GTV, absolute tumor size) had a 
mean of 1.78 cm3 (± 1.67) with a range from 0.15 to 7.70 cm3. Mean GTV/brain ratio [relative tumor size, 
(n=16)] was 8.32 %  (± 8.55) and the PTV/brain ratio could be derived for 16 cats with a mean of 33.18 %  
(± 34.00).		The majority of cats presented with altered neurologic status and without epileptic seizures 
(n=20). One cat presented with epileptic seizures only (Table 1, case no. 22) and one cat with both altered 
neurological status and epileptic seizures (Table 1, case no. 21).  
Treatment 
Twenty-one patients were treated with various definitive-intent daily-fractionated protocols (Table 1). One 
patient (Table 1, case no. 20) was treated with a highly conformal definitive-intent hypofractionated 
radiation protocol (3x8Gy) delivered every other day and received less than 40.00 Gy of total dose. Total 
doses ranged from 24.00 to 45.00 Gy, with a mean total dose 41.63 Gy (± 4.33). Fraction sizes ranged 
from 2.25 to 8.00 Gy, with a mean of 3.32 Gy (± 1.29). Twenty-one cats were treated using a daily 
(Monday-Friday) treatment schedule. Only case no. 20 (Table 1) was treated on a Monday-Wednesday-
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Friday schedule. All cats completed the full course of the planned radiation therapy. The respective EQD2 
were 36.00 to 49.70 Gy2, with a mean of 45.79 Gy2 (± 2.74). Mean overall treatment time was 19.6 days 
(5 - 29 days). Pretreatment corticosteroid treatment with prednisolone was given to 20/22 cats with a mean 
dose of 0.66 mg/kg (± 0.41) once daily orally and tapered to mean doses of 0.58 mg/kg (± 0.43) once daily 
orally post RT (p=0.076). Three cats received antiepileptic treatment consisting of either phenobarbital 
(n=2) or levetiracetam (n=1) pre-, during and post RT. Two of these cats had epileptic seizures at initial 
presentation and one received phenobarbital prophylactically and was tapered off the medication after RT, 
as no epileptic seizures were observed.  
 
Outcome and prognostic factors 
Median follow-up time for censored cases (n=8, still alive or lost to follow-up) was 575 days (95%CI: 
464-686). Fourteen of the 22 cats died during the study period. Death was attributed to the brain tumor or 
possible treatment related toxicity in 5 of the 14 cats (35.7%). In the 64.3% of animals that died due to 
other causes, death was related to other neoplastic disease [n=4, histiocytic sarcoma in the liver (Table 1, 
case no. 4), lymphosarcoma in the bladder (Table 1, case no. 5), oral sarcoma (Table 1, case no. 10), 
intestinal lymphoma (Table 1, case no. 13)], tumor-unrelated medical problems (not accompanied with 
neurologic symptoms) like hyperthyroidism (Table 1, case no. 11), cardiac failure with dilated atria, 
arrhythmia and mild pericardial effusion (Table 1, case no. 14) or pyothorax (Table 1, case no. 19). In two 
cases (Table 1, case no. 3 and 17) the cats died at home with general weakness. Tumor recurrence could 
not be ruled out, because no necropsy was performed so the real cause for death remains unknown in these 
two cases. 
Based on medical records and owner communication, clinical and neurologic status improved in 21/22 
(95.5%) cats, compared to the pre-treatment complaints. One of the 22 cats was judged to have stable 
clinical signs (Table 1, case no. 18). In the patient, in which epileptic seizures was the only presenting 
complaint, it was difficult to determine whether seizure control was attributable to reduction of 
tumor/edema or to anti-epileptic medication.  
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A total of 10 post-radiotherapy diagnostic imaging examinations were performed in 6 patients. CT 
was performed 4 times (n=3 cats), and MRI was performed in 6 times (n=3 cats). On MRI one cat with a 
meningioma showed partial remission at 6 months post RT (Table 1, case no. 1), a second cat with a 
meningioma showed stable disease at 3, 6 and 12 months post RT (Table 1, case no. 6). Another cat with a 
pituitary gland tumor showed stable disease on MRI at 6 and 12 months post RT (Table 1, case no. 12). In 
the CT of one cat 6 months post RT the tumor was in partial remission (the 12 months re-check CT of the 
same cat was made at another clinic and tumor volume was not measured) (Table 1, case no.15). Tumors 
of two cats were measured 24 months post RT, one cat still showed stable disease (Table 1, case no. 17) 
and the other cat was scanned upon re-occurrence of neurologic signs and had a disease progression on CT 
(Table 1, case no. 3). Overall, 7 cats (31.8%) were considered to have a disease progression either on 
increased volume based on imaging (n=1) or on progression of neurological signs (n=6). 
The median progression free survival (PFS) time for all 22 cases was 510 days (95%CI: 51;969). 
The proportion free of progression at 1 year was 55.7% (95%CI: 33;78) (Figure 1). Of the 9 cats that died 
within the first year after RT, 7 (77.8%) died of causes un-related to the brain tumor (Table 1, case no. 4, 
5, 10, 11, 13, 14 and 19) and 2 (22.2%) died because of the brain tumor or treatment related toxicity 
(Table 1, case no. 18 and 21). No difference was seen in PFS between the patients treated at the different 
institutions (p=0.634). At the time of tumor progression, two cats were re-irradiated resulting in an 
additional progression-free interval of 223 and 281 days (Table 1, case no. 3 and 17). Both cases were 
censored from analysis of OS at the start of the second course of radiation therapy. Neither the patient 
related (age, sex), tumor related (meningioma/ non-meningioma, meningioma/ pituitary tumor, tumor size, 
tumor location) or the treatment related parameters (dose of radiation [total radiation dose or EQD2], 
corticosteroid dose at first RT, overall treatment time, treatment institution) were associated with PFS. 
Median overall survival time (OS) was 515 days (95%CI: 66;964). The proportion alive at 1 year 
was 56 % (95%CI: 33;79) and at 2 years 37% (95%CI: 15;60) (Figure 2). No difference was seen in OS 
between the patients treated at the different institutions (p=0.695). None of the tested variables had a 
statistically detectable influence on OS.  
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Discussion  
Intracranial tumors causing neurological signs in cats are often of extra-axial and non-infiltrative 
nature and can be successfully treated with surgery.1-5 Meningiomas with and without neurological signs 
are the most common intracranial tumors in cats and postoperative median survival times were found to 
range between 22.8 to 37 months.1, 2, 5 For feline patients with tumors in less accessible locations such as 
tentorially located meningiomas, survival time was found to decrease to 19 months postoperatively.3 The 
risk of fatal intra- or postoperative complications ranged between 6-19%2, 3, 5 and depending on primary 
tumor location, the postoperative recurrence rate was 12-21%1, 2, 5 and 100%3. In these retrospective 
studies should be a selection bias considered of only including surgically amenable tumors. 
For cats with inoperable tumors however, literature findings are scarce and limited to cases of 
pituitary neoplasia and a case report of a cat with oligodendroglioma treated with radiation therapy.10-13, 20 
Surprisingly, amelioration of neurologic symptoms was rapid and often complete in most cats and survival 
times increased from a median of 1.1-1.7 months if treated with corticosteroids only1 to a range of 5.5-
20.5 months after radiation.10-13 These results are difficult to compare to our findings, as in the cats treated 
for pituitary tumors only 38.9% had neurologic symptoms and most of them were treated because of 
pituitary-dependent endocrine disease. However, as it is known from dogs with pituitary tumors treated 
with radiation therapy, radiation therapy prolonged survival also in non-neurologic patients by delaying 
the onset of neurologic signs.21 In dogs with an intracranial primary tumor and neurologic signs, 
fractionated radiation therapy is often considered the treatment of choice with durable tumor control in the 
range of 19.2-25.2 months.6-9  
In this study, the outcomes of cats with intracranial tumors presented with neurological signs were 
retrospectively compiled. Cases were sought from 4 institutions, and only 3 institutions could contribute 
patients. This fact indicates the scarcity of brain tumors in cats. After radiation therapy, the neurological 
status improved in all but one cat (95.5%). Median overall survival time was 17.2 months, with 56% of 
cats alive at one year after therapy. Surprisingly, only seven patients (32%) were considered to have 
disease progression during the time of follow-up. Most patients (9/14) died of other neoplastic diseases or 
unrelated medical problems. Upon recurrence of disease, two cats in this cohort were re-irradiated and 
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attained an additional progression-free interval of 7.4 and 9.2 months (Table 1, case no. 3 and 17). None 
of the investigated factors such as age, sex, treatment institution, tumor location (extra-axial, intra-axial, 
pituitary), tumor type, tumor size, regions of brain affected, total dose, EQD2, corticosteroid dose at first 
RT, nor overall treatment time were found to correlate with progression-free or overall survival time.   
We acknowledge limitations of this study that should direct future research approaches:  A) The 
cats were treated at different institutions, with various non-standardized radiation protocols in terms of 
fraction size, total dose, overall treatment times, target volumes and treatment planning practices, 
equipment and patient position verification. In order to not skew the data into a direction, we decided to 
keep patients treated with all fraction schedules in the investigated group. B) Standardized neurological 
evaluation, severity of neurological signs, and routine follow-up diagnostic imaging were not available, 
which should constitute an important focus for further evaluation of tumor response to radiation therapy. 
C) Improvement of the clinical signs could - at least in part - also be attributed to medical supportive 
treatment such as corticosteroids. D) The patient population consisted of a heterogeneous group, with 
varying unconfirmed tumor types. Presumptive tumor diagnoses were made according to advanced 
diagnostic imaging techniques.14 Most of the tumors were meningiomas (50%) or pituitary adenomas 
(36%), which are commonly non-infiltrative and hence less aggressive. Furthermore, due to the limited 
number of patients, statistical analysis for each tumor type was not performed. E) The patients were 
referred for radiation therapy and the possibility of resectability was not uniformly judged. F) Due to the 
retrospective nature of the study and the lack of follow up imaging it was not in every case possible to 
differentiate tumor progression from radiation toxicity as the cause of recurring neurologic signs. 
In conclusion, findings of this study suggest radiation therapy as viable treatment option for cats 
with intracranial tumors presented with neurological signs. Case selection should focus on inoperable 
disease or patients with an estimated high peri- and postoperative risk.  
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Figure Legends: 
 
Figure 1: Median progression free survival (PFS). The dotted line marks 1-year. Tick marks: cats that 
were free of progression of measurable tumor and of progression of neurologic signs and that were alive at 
the time of data collection were censored for PFS analysis. Of the 9 cats that died within the first year after 
RT, 7 (77.8%) died of causes un-related to the brain tumor and 2 (22.2%) died because of the brain tumor 
or treatment related toxicity. 
 
Figure 2: Median overall survival (OS): The dotted line marks 1-year. Tick marks: cats that were still alive 
at the time of data collection or lost to follow-up were censored at the last date of contact. 
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Table 1: Individual patient data regarding tumor type and size, radiation protocols, progression free survival 
and overall survival  	
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